Kite Pharma opens state-of-the-art T-cell therapy manufacturing facility
![](/46/pdcnewsitem/04/13/92/kite%20pharma.gif)
43,500-sq-ft plant next to Los Angeles International Airport will support production of engineered CAR and TCR cancer immunotherapies.
Kite Pharma has marked the official opening of its new commercial manufacturing facility in El Segundo, California. Over 300 employees, investors and company partners attended the unveiling of the 43,500-sq-ft, state-of-the-art plant. The facility has been designed to produce chimeric antigen receptor (CAR) and T-cell receptor (TCR) product candidates for clinical trials, as well as for the potential launch and commercialization of Kite’s lead CAR T-cell product candidate, KTE-C19, which is in clinical study for the treatment of chemorefractory diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Kite anticipates commercial launch of KTE-C19 in 2017.
The facility is estimated to have the capacity to produce up to 5,000 patient therapies per year. The plant’s location, adjacent to Los Angeles International Airport, is intended to expedite receipt and shipment of engineered T-cells from and to patients across the United States and Europe.
“Establishing world-class manufacturing capability has always been a priority for Kite,” said Timothy Moore, Kite’s Executive Vice President of Technical Operations. “Through our continuous efforts to optimize manufacturing, supply chain and quality control, our proprietary process now reduces the time from when a patient’s materials are shipped to our facility to when the engineered T cells are returned to the patient to approximately 14 days, one of the fastest in the industry.”
Underscoring the company’s focus on execution and commitment to the future delivery of immuno-oncology therapies, the El Segundo facility is expected to be operational by the end of this year for clinical production, less than two years after the site groundbreaking in February 2015. The El Segundo facility will complement Kite’s existing clinical manufacturing facilities in Santa Monica, California, that are currently producing therapies for Kite’s ongoing clinical trials.
“We are excited and proud to celebrate the opening of our El Segundo manufacturing facility, the latest milestone in our mission to deliver a potentially transformative therapy to patients with a significant unmet need,” said Arie Belldegrun, Kite’s Chairman, President and CEO. “If approved by the FDA, this site will become a model factory serving patients all over the country. We will also continue to innovate and introduce next generation manufacturing technologies at our facility.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance